Emerging evidence supports the use of SGLT2 inhibitors in improving hepatic steatosis, reducing liver fibrosis, and enhancing metabolic parameters in patients with NAFLD and type 2 diabetes [6]. Here, SLC5A2 is linked to Hepatic fibrosis.